Invention Grant
- Patent Title: Ang2 antibodies
-
Application No.: US14709514Application Date: 2015-05-12
-
Publication No.: US09695241B2Publication Date: 2017-07-04
- Inventor: Donmienne Doen Mun Leung , Jianghuai Xu
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Robert B. Johnson
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; C12P21/06 ; C12P21/08 ; C07H21/02 ; C07K16/28 ; C07K16/22
Abstract:
The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
Public/Granted literature
- US20150329627A1 Ang2 Antibodies Public/Granted day:2015-11-19
Information query
